Investigational drug · Phase 3
Del-desiran
Also called: AOC 1001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for DM1, Myotonic Dystrophy, Myotonic Dystrophy 1.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
2
Any phase or sponsor naming "Del-desiran"
First trial start
2022
Aug 4, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Del-desiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- DM1
- Myotonic Dystrophy
- Myotonic Dystrophy 1
- Myotonic Disorders
- Myotonia
- Steinert Disease
- Myotonic Dystrophy Type 1
- Steinert Myotonic Dystrophy
- Myotonic Dystrophy Type 1 (DM1)
- Dystrophy Myotonic
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Del-desiran" as an intervention, largest first.
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1Pivotal-lookingEnrolling by invitation
Avidity Biosciences, Inc.Industry
NCT07008469 · 199 participants (planned) · Start Jun 26, 2025 · Primary completion Oct 2030
Drug: Del-desiran (AOC 1001) · For: Myotonic Dystrophy Type 1; DM1; Myotonic Dystrophy and 5 more
Sites: Los Angeles, California; Stanford, California; Denver, Colorado · 35 sites in all
- Global Study of Del-desiran for the Treatment of DM1Pivotal-lookingCompleted
Avidity Biosciences, Inc.Industry
NCT06411288 · 159 participants · Start May 30, 2024 · Primary completion Jul 23, 2026
Drug: AOC 1001 (del-desiran); Placebo · For: DM1; Myotonic Dystrophy; Myotonic Dystrophy 1 and 7 more
Sites: Stanford, California; Denver, Colorado; Gainesville, Florida · 34 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.
Kwan TT, Meng Q, Delos Santos N, et al. · Mol Ther 2026
- An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
Johnson NE, Tai LJ, Hamel JI, et al. · N Engl J Med 2026
Also in development for DM1
- zeleciment basivarsenDYNE-101Phase 32 trials
Dyne Therapeutics · Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.